Mso489, the single purpose is to minimise the small companies' share in the market and block harm reduction. The main sufferers are the smaller businesses which offer a wide range of blends. The big tobacco players with smaller product ranges produced in higher quantities face less registration fees.
It was mentioned elsewhere on the 'net that Marlboro will face fees of less than £10k (petty cash for them) whereas some of the smaller snuff and vape manufacturers could face fees stretching into the millions, and in some cases approaching 100x annual turnover.
For a pipe example, look at how many products come out of GH and SG (a small company, even after remerging) compared with the likes of Condor or St Bruno. The smaller and more diverse companies are being penalised for their diversity, which is the very thing that keeps them viable. Glynn Quelch was instantly removed from the blending scene, Molens de Kralingse was instantly removed from the snuff scene. Wilsons of Sharrow saw their range drop by over 80%, and other snuff makers followed suit. I don't think we've even begun to see the full effects with the pipe scene yet.
I do not believe for one minute that this unfairness where the big companies pay less than the smaller ones was unintentional. It started under the auspices of health and reducing the uptake by young people, and through back room deals, big tobacco swung things in their favour. It's the only explaination. Even the EU isn't incompetent enough for this to happen by accident.